The debate over the proposed Biotech Act in the EU has revealed a split among member states regarding the extension of monopoly rights for certain treatments. While some countries support the measure as a way to encourage biotech investment in Europe, others express concerns about its potential impact on patient access and healthcare budgets. The incoming Irish presidency is urging swift negotiations to advance the Act amid competitive pressures.